Our Vision
Unite the power of immunity and nanoparticle, change the future of patients
Nowadays, one out of two people will get cancer at least once in their lifetime. There are many patients and their families around me who are battling cancer. Some are fortunate enough to survive, while others fall halfway through their battle, despite their best efforts. I have been involved in the research and development of new cancer drugs with the hope of developing as many weapons as possible to fight cancer and to increase the number of people who survive the battle against cancer. I encountered the idea of cancer immunotherapy, a treatment technology for the 21st century that utilizes the function of the immune system in cancer treatment. This technology can be further boosted by nanotechnology, which has the potential to dramatically increase the effectiveness of cancer immunotherapy. I therefore established our company with the aim of bringing the union of nanotechnology and cancer immunotherapy, or “nano-immunotherapy”, to patients. I will devote my entire life to the realization of rapid social implementation of this next-generation technology, while mobilizing the power of researchers, physicians, entrepreneurs, and investors.
mRNA based therapies have become well-known through coronavirus vaccines during the pandemic and the awarding of the Nobel Prize in Medicine in 2023 for development of this technology. However, mRNA can only exist as a therapeutic drug when combined with another innovation: lipid nanoparticles (LNPs). United Immunity’s "Myeloid Targeting Platform™" is game changer technology that originated from Japanese research and allows active and selective targeting of mRNA payload to immune cells. We will foster this innovation so that our technology can help as many patients as possible in the event of a new pandemic or in a situation where mRNA medicines are needed. Our philosophy is to rapidly translate our research results into much needed therapies to patients.